Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma

Annals of Oncology : Official Journal of the European Society for Medical Oncology
F L ClarkW N Patton

Abstract

Chronic carriers of Hepatitis B virus (HBV) infection, who are treated for malignant lymphoma, are at high risk of mortality from reactivated HBV infection. We report a case of a 29-year-old male chronic HBV carrier who developed fulminant reactivated HBV infection following intensive chemotherapy for stage IVB large cell B-cell non-Hodgkin's lymphoma associated with extensive central nervous system and bone marrow involvement. Prior to chemotherapy the patient had normal liver function tests and was negative for HBV DNA by semiquantitative PCR assay. Fulminant HBV reactivation was confirmed following clinical deterioration, massive rises in hepatic transaminases (peak alanine aminotransferase = 2,850 U/l), liver biopsy and rising levels of serum HBV DNA. Following treatment with lamivudine 150 mg bd for 18 weeks dramatic and sustained recovery ensued. Symptoms and liver function tests improved within days and HBV DNA became negative within 12 weeks. Our patient later died from relapsed lymphoma but without evidence of reactivated HBV infection. We advise that lamivudine should be considered during intensive chemotherapy treatment of chronic carriers of HBV.

Citations

Feb 26, 2000·British Journal of Haematology·F SilvestriM Baccarani
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Winnie YeoPhilip J Johnson
Mar 3, 2005·Journal of Gastroenterology and Hepatology·Akihito TsubotaHiromitsu Kumada
Aug 3, 2005·American Journal of Clinical Oncology·Winnie YeoPhilip J Johnson
Aug 17, 2006·Journal of Gastroenterology and Hepatology·Debbie M NathanPeter R Gibson
Feb 28, 2008·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Chiun HsuPei-Jer Chen
Mar 13, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Arzu OguzAhmet Karaman
Nov 30, 2004·Liver International : Official Journal of the International Association for the Study of the Liver·M S DaiT Y Chao
Jan 28, 2006·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Winnie Yeo, Philip J Johnson
Aug 2, 2000·Journal of Gastroenterology and Hepatology·N Stace
Jun 18, 2003·Journal of Clinical Gastroenterology·Nicole D SimpsonAijaz Ahmed
Aug 29, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·George K K LauRaymond Liang
Sep 6, 2007·Leukemia & Lymphoma·Timucin CilAbdurrahman Isikdogan
Jun 1, 2008·Hepatology International·George K K Lau
Jun 2, 2011·Clinical and Experimental Nephrology·Waka Ohishi, Kazuaki Chayama
Mar 7, 2003·Journal of Pediatric Hematology/oncology·Anna Rita GigliottiRaffaella Giacchino
Dec 21, 2004·Breast Cancer Research and Treatment·Winnie YeoPhilip J Johnson
Jun 18, 2004·Journal of Korean Medical Science·Jin-Hee AhnWoo Kun Kim
Feb 26, 2009·Current Infectious Disease Reports·Anthony Post, Shweta Nagendra
Jan 19, 2011·Liver International : Official Journal of the International Association for the Study of the Liver·Bruno Roche, Didier Samuel

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.